Shots:
- Quebec government has stated province intention to shift towards biosimilars and follows the transition policies implemented by British Columbia, Alberta & New Brunswick
- The expanded use of biosimilars is expected to generate annual savings of $100M for the public drug insurance plan and its insured parties that can be reinvested in healthcare and innovative new drugs
- Under the policy, the transition from reference biologic to a biosimilar will take place under the supervision of treated physicians by April 12, 2022
Click here to read full press release/ article | Ref: Quebac| Image: Quebec
The post Quebec Reports the Intention on Implementing Shift Towards Biosimilars first appeared on PharmaShots.
